Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DLL3 x B7H3 bispecific ADC
- Development stage
- Preclinical
- Lead developer
- GeneQuantum Biosciences
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
DLL3 x B7H3 bispecific ADC is a novel bispecific antibody-drug conjugate (ADC) developed by GeneQuantum Healthcare, designed to target both Delta-like ligand 3 (DLL3) and B7-H3 (CD276). This therapeutic candidate is engineered to address the significant molecular heterogeneity and treatment resistance observed in small cell lung cancer (SCLC). DLL3 is an inhibitory ligand of the Notch pathway that is highly expressed in neuroendocrine SCLC subtypes (SCLC-A and SCLC-N), while B7-H3 is homogeneously overexpressed across all SCLC subtypes, including the chemo-immunotherapy resistant SCLC-P variant. The ADC utilizes a topoisomerase 1 inhibitor (Top1i) payload conjugated to a bispecific antibody format. Preclinical data presented at AACR 2026 demonstrated that the lead candidate exhibits potent cellular internalization and target-specific cytotoxicity, with superior antitumor activity in patient-derived xenograft (PDX) models compared to monospecific ADC benchmarks, particularly in refractory SCLC-P models.
- Other names
- DLL3/B7H3 bispecific ADCDLL3 x B7-H3 bispecific ADCDLL-3 x B7-H3 bispecific ADCDLL 3 x B7-H3 bispecific ADC
02
Targets
TOP1 (DNA Topoisomerase I)B7-H3DLL3 (Delta-like ligand 3)
Beyond the preview
Go deeper on DLL3 x B7H3 bispecific ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DLL3 x B7H3 bispecific ADC.